Anileridine
 | |
| Systematic (IUPAC) name | |
|---|---|
|
Ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate | |
| Clinical data | |
| AHFS/Drugs.com | monograph |
| Routes of administration | Tablets, injection |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | > 95% |
| Metabolism | Hepatic |
| Identifiers | |
| CAS Number |
144-14-9  |
| ATC code | N01AH05 (WHO) |
| PubChem | CID 8944 |
| IUPHAR/BPS | 7115 |
| DrugBank |
DB00913 |
| ChemSpider |
8600 |
| UNII |
71Q1A3O279 |
| KEGG |
D02941 |
| ChEBI |
CHEBI:61203 |
| ChEMBL |
CHEMBL1201347  |
| Chemical data | |
| Formula | C22H28N2O2 |
| Molar mass | 352.47 g/mol |
| |
| |
| Physical data | |
| Melting point | 83 °C (181 °F) |
| (what is this?) (verify) | |
Anileridine (trade name: Leritine) is a synthetic analgesic drug and is a member of the piperidine class of analgesic agents developed by Merck & Co. in the 1950s.[1] It differs from pethidine (meperidine) in that the N-methyl group of meperidine is replaced by an N-aminophenethyl group, which increases its analgesic activity.
Anileridine is no longer manufactured in the US or Canada.[2] Anileridine is in Schedule II of the Controlled Substances Act 1970 of the United States as ACSCN 9020 with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.83 for the dihydrochloride and 0.73 for the phosphate [3] It is also under international control per UN treaties.
Administration
Pharmacokinetics
Anileridine usually takes effect within 15 minutes of either oral or intravenous administration, and lasts 2–3 hours.[5] It is mostly metabolized by the liver.
References
- ↑ U.S. Patent 2,897,204
- ↑ "Discontinued Prescription Drug Products". Canadian Pharmacists' Association. Retrieved 28 July 2008.
- ↑ http://www.deadiversion.usdoj.gov/fed_regs/quotas/2014/fr0825.htm
- ↑ "Pharmaceutical Information - LERITINE". RxMed. Retrieved 16 June 2010.
- ↑ "Anileridine Consumer Information". MedicineNet. Retrieved 28 July 2008.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||